ClinicalTrials.gg
CompletedNCT04054050Updated Oct 9, 2026

Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis

An interventional study of Light therapy in Multiple Sclerosis, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Multiple Sclerosis by Johns Hopkins University — 4 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Johns Hopkins University.

Enrollment
13th of 18
27 · median 48
Started
2021
with 2 others
No phase
8 of 20
none open now
Registered
12th of 20
by date

Among the 20 studies in Multiple Sclerosis by Johns Hopkins University, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 with no phase, and was the 12th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 20 studies in Multiple Sclerosis by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Multiple Sclerosis by Johns Hopkins University, or all of them as a file.
02

Study summary

Sleep disturbance is common in people with multiple sclerosis (MS) and contributes to diminished quality of life. Bright light therapy may be an innovative strategy to reduce sleep disturbance in MS, possibly through its effects on a subtype of retinal ganglion cells that help regulate circadian rhythms and sleep. This pilot study will evaluate whether, in people with MS, bright light therapy reduces sleep disturbance and explore whether light therapy improves function of these cells.

Read the detailed description

Multiple sclerosis (MS), an inflammatory and neurodegenerative disorder of the central nervous system (CNS), is the most common cause of progressive neurologic dysfunction in early to middle adulthood. People with MS are a markedly high risk for sleep disturbance. Estimates of the lifetime prevalence of sleep disturbance in MS reach 50%; sleep disturbance is also associated with excess MS-associated morbidity and diminished quality of life. Despite the high burden of impaired sleep and its contribution to adverse MS outcomes, effective approaches to treat and ameliorate disturbed sleep in people with MS remain poorly understood. There is unmet need to develop safe and effective rehabilitative alternatives to mitigate sleep disturbance in MS. Prior research supports the use of timed bright light therapy (LT) as one such approach for insomnia and sleepiness in those with sleep disorders or other neurologic diseases. Yet, the safety and potential effectiveness of timed LT have yet to be tested in MS. The goal of the proposed study is to conduct a detailed intervention study testing if timed bright LT in people with MS is 1) safe (primary outcome) and 2) potentially effective for reducing sleep disturbance (specifically, reducing insomnia, fatigue and improving sleep efficiency, quantity and quality as secondary outcomes). The study will also explore whether LT stimulates a novel subtype of retinal ganglion cells which are central to the regulation of circadian rhythms and sleep.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • sleep disturbance
  • insomnia
  • fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MS
  • Evidence of sleep disturbance
  • Stable on immunomodulatory MS therapy or no therapy for at least 6 months prior to study initiation
  • Stable on antidepressants for at least 3 months prior to study initiation and no evidence
  • Stable on fatigue medication for at least 3 months prior to study initiation
  • Willing and able to provide and follow study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence of cognitive impairment
  • Low risk for sleep disordered breathing
  • Other comorbid ophthalmologic disorders (e.g. cataracts, glaucoma, blindness)
  • Traveled across two time zones within 90 days of study screening.
  • Not participating in shift work
  • MS relapse or history of acute optic neuritis within 30 days
  • No prior history of bipolar disorder
  • No evidence of current depression
  • Diagnosis of severe periodic limb movement disorder or severe restless legs syndrome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Light therapy

    Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).

    Other: Light therapy

Interventions

  • OtherLight therapy

    Bright light (10,000 lux) therapy will be administered via a light box.

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    The number of adverse events will be documented and categorized by organ system

    Time frame: 2 weeks

Secondary outcomes

  1. Change in sleep quantity as assessed by the Pittsburgh Sleep Quality Index (PSQI)

    The PSQI has a sub-component that quantifies sleep quantity. The investigators will assess change in sleep quantity (difference in minutes) as assessed by this sub-component.

    Time frame: Baseline, 2 weeks

  2. Change in sleep efficiency as assessed by the Pittsburgh Sleep Quality Index (PSQI)

    The PSQI has a sub-component that quantifies sleep efficiency. The investigators will assess change in sleep efficiency (difference in minutes) as assessed by this sub-component.

    Time frame: Baseline, 2 weeks

  3. Change in overall sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)

    The PSQI has an overall score that ranges from 0 to 21. The investigators will assess change in the overall PSQI score.

    Time frame: Baseline, 2 weeks

  4. Change in insomnia severity as assessed by the Insomnia Severity Index (ISI)

    The ISI is validated questionnaire assessing insomnia from which a total score is calculated and ranges from 0 to 28. The investigators will calculate change in the overall ISI score.

    Time frame: Baseline, 2 weeks

  5. Change in daytime sleepiness as assessed by the Epworth Sleepiness Scale (ESS)

    The ESS is validated questionnaire assessing daytime sleepiness from which a total score is calculated and ranges from 0 to 24. The investigators will calculate change in the overall ESS score.

    Time frame: Baseline, 2 weeks

  6. Change in fatigue severity as assessed by the Neuro-QoL fatigue questionnaire

    The Neuro-QoL fatigue severity score (short form) is a validated 8-question assessment of fatigue from which T-scores ranging from 0 to 100 can be obtained. The investigators will assess change in Neuro-QoL fatigue severity.

    Time frame: Baseline, 2 weeks

07

Study locations

1 site
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21287, United States
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be available to other researchers. Since the study will enroll only 24 individuals, even if stripped of identifiers, it may still be possible to identify participants. Thus, data will not be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Dec 2025, 58 months.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 58 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Dec 2025, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2019
First posted
Aug 13, 2019
StartActual
Feb 22, 2021
Primary completionActual
Dec 30, 2025was Sep 2025
CompletionActual
Jan 30, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2025→Dec 30, 2025
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Sep 30, 2025→Dec 30, 2025
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04054050
Responsible party
Sponsor
First posted
Aug 13, 2019
Start date
Feb 22, 2021
Primary completion
Dec 30, 2025
Completion
Jan 30, 2026
Last update
Oct 9, 2026

Study contacts

Kathryn C Fitzgerald, ScD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion